Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Intangible assets

v3.23.1
Intangible assets
 12 Months Ended
Dec. 31, 2022
Intangible assets

10. Intangible assets

   

Software

£

    

Patent and

licence costs

£

    

Total

£

  
Cost                        
At January 1, 2021     49,613       464,881       514,494  
Additions             123,191       123,191  
At December 31, 2021     49,613       588,072       637,685  
Additions     -       124,485       124,485  
At December 31, 2022     49,613       712,557       762,170  
                         
Amortization                        
At January 1, 2021     23,015       67,642       90,657  
Charge for the year     16,521       46,930       63,451  
At December 31, 2021     39,536       114,572       154,108  
Charge for the year     7,125       47,921       55,046  
At December 31, 2022     46,661       162,493       209,154  
                         
Net book value                        
At December 31, 2022     2,952       550,064       553,016  
                         
At December 31, 2021     10,077       473,500       483,577  

 

The amortization charge for the year is recognized within research and development costs in the statements of comprehensive loss.

 

 

TC BIOPHARM (HOLDINGS) PLC

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)